Delving into the Latest Updates on Trop2/CD3 bispecific antibody(Arbele) with Synapse

Overview

Basic Info

Drug Type

Bispecific T-cell Engager (BiTE)

Synonyms

TROP-2/CD3 bispecific antibodies (Arbele)

Target

CD3 x Trop-2

Mechanism

CD3 modulators(T cell surface glycoprotein CD3 modulators), CD3 stimulants(T cell surface glycoprotein CD3 stimulants), Trop-2 inhibitors(Tumor-associated calcium signal transducer 2 inhibitors)

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease

Active Indication

Gastrointestinal NeoplasmsColorectal CancerPancreatic Cancer+ [1]

Inactive Indication-

Originator Organization

Arbele Corp.Startup

Active Organization

Arbele Corp.Startup

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

T-cell-based therapies have emerged as one of the most clinically effective ways to target solid and non-solid tumors. HER2 is responsible for the oncogenesis and treatment resistance of several human solid tumors. As a member of the HER family of tyrosine kinase receptors, its over-activity confers unfavorable clinical outcome. Targeted therapies directed at this receptor have achieved responses, although development of resistance is common. We explored a novel HER2/CD3 bispecific antibody (HER2-BsAb) platform that while preserving the anti-proliferative effects of trastuzumab, it recruits and activates non-specific circulating T-cells, promoting T cell tumor infiltration and ablating HER2(+) tumors, even when these are resistant to standard HER2-targeted therapies. Its in vitro tumor cytotoxicity, when expressed as EC₅₀, correlated with the surface HER2 expression in a large panel of human tumor cell lines, irrespective of lineage or tumor type. HER2-BsAb-mediated cytotoxicity was relatively insensitive to PD-1/PD-L1 immune checkpoint inhibition. In four separate humanized mouse models of human breast cancer and ovarian cancer cell line xenografts, as well as human breast cancer and gastric cancer patient-derived xenografts (PDXs), HER2-BsAb was highly effective in promoting T cell infiltration and suppressing tumor growth when used in the presence of human peripheral blood mononuclear cells (PBMC) or activated T cells (ATC). The in vivo and in vitro antitumor properties of this BsAb support its further clinical development as a cancer immunotherapeutic.

100 Deals associated with Trop2/CD3 bispecific antibody(Arbele)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Gastrointestinal Neoplasms	Preclinical	HK	Arbele Corp.Startup	22 Mar 2024
Colorectal Cancer	Preclinical	CN	Arbele Corp.Startup	-
Pancreatic Cancer	Preclinical	CN	Arbele Corp.Startup	-
Stomach Cancer	Preclinical	CN	Arbele Corp.Startup	-